Effect of once daily (o.d.) mometasone/indacaterol/glycopyrronium (MF/IND/GLY) vs o.d. MF/IND and twice daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) with respect to age, age at asthma-onset and BMI at baseline: Subgroup analysis from IRIDIUM study

Conclusion: High-dose MF/IND/GLY provided similar benefits irrespective of baseline subgroups. Physicians looking to personalise treatment decision would be better served looking to pts preference factors (e.g., o.d./b.i.d. regimen, device type, availability of digital companion) than those clinical parameters explored here.

Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Kerstjens, H. A., Lawrence, D., Mezzi, K., Brittain, D., Jaumont, X., Chapman, K. R. Tags: 05.01 - Airway pharmacology and treatment Source Type: research